AscellaHealth Assesses New, Anticipated Specialty Treatments
The specialty drug landscape continues to be a dynamic space, as new agents enter the market and existing ones gain FDA approval for additional indications. Global health care and specialty pharmacy solutions organization AscellaHealth recently released its quarterly breakdown of insights into treatments within the segment.
The Q3 2023 Specialty & Rare Pipeline Digest examines new approvals and launches of specialty drugs, including biosimilars, generics, and cell and gene therapies, as well as ones in the pipeline.
© 2024 MMIT
Related Posts
February
9
2023 Outlook: Expect Rare Disease, Cancer, Immunology Drugs to Have Big Impact
READ MORE
September
14
Now That Humira Biosimilars Have Launched, What Are Lessons Learned for Stelara Biosimilars?
READ MORE
July
13